Premium
Clearance of liposomal gadolinium: In vivo decomplexation
Author(s) -
Unger Evan C.,
Fritz Thomas A.,
Tilcock Colin,
New Terri E.
Publication year - 1991
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.1880010613
Subject(s) - gadolinium , in vivo , liposome , medicine , chemistry , nuclear medicine , pathology , biology , microbiology and biotechnology , biochemistry , organic chemistry
The contrast agents gadolinium‐DTPA (diethylenetriaminepentaacetic acid), Gd‐DOTA (tetraazacyclododecanetetraacetic acid), and Gd‐HP‐DO3A (1,4,7‐tris[carboxymethyl]‐10‐[2′hydroxypropyl]‐1,4,7,10‐tetraazacyclododecane) are used in humans as extracellular contrast agents. Although free Gd + ion is toxic, the intact Gd 3+ complexes are rapidly excreted and are relatively nontoxic. Decomplexation with release of free gadolinium is a relevant clinical concern in patients with altered renal clearance. Blood pool contrast agents currently under development may have longer clearance half‐lives and be more prone to decomplexation. The present study was designed to evaluate the clearance of liposomally encapsulated Gd 3+ complexes (DTPA, DOTA, and HP‐DO3A). The macrocyclic compounds had more rapid and complete clearance than DTPA (P <.05). Parallel studies with carbon‐14 and Gd‐153‐labeled complexes showed significant differences (P <.05) in the amount of these isotopes retained in the heart, kidney, lungs, and spleen, providing strong supportive evidence for in vivo decomplexation.